drugset / Trial / NCT01711775
A Pharmacokinetic Study of Aleglitazar in Healthy Chinese Volunteers
Non-randomizedSingle-groupOpen-label
Summary
This single-center, non-randomized, open-label study will assess the pharmacokinetics of aleglitazar after administration of single and multiple oral doses in healthy Chinese volunteers. Subjects will receive a single oral dose of aleglitazar on Day 1 and repeated oral doses once daily from Day 5 to Day 14. Anticipated time on study, including screening and a 2-week follow-up, is up to 8 weeks.
Timeline
- Start
- 2012-11
- Primary completion
- 2012-12
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aleglitazar | Small molecule | 0.15 mg | Oral |
Indications
No indication recorded.